Skip to content

Herbal Teas on Bone Health in an Osteopenic Population

Assessing the Efficacy of Herbal Teas on Bone Health in an Osteopenic Population: OsTea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03480126
Acronym
OsTea
Enrollment
35
Registered
2018-03-29
Start date
2018-06-01
Completion date
2019-08-27
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteopenia

Brief summary

The project goal is to identify if herbal teas consumed three times per day over a period of three months can improve these markers of bone health as well as improve quality of life (QOL) compared to women taking placebo by increasing osteoblast activity, decreasing osteoclast activity, increasing nocturnal melatonin levels and by decreasing C-reactive protein (CRP) and cortisol levels. Our central hypothesis is that these herbal teas will improve both objective and subjective measures of bone health in a population with osteopenia not taking this regimen by reducing osteoclast activity and increasing osteoblast activity and by reducing stress and anxiety.

Interventions

OTHERHerbal Teas

Steeped tea ingested 3 times a day for 3 mos

Sponsors

Duquesne University
CollaboratorOTHER
Paula Witt-Enderby
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* male or female with osteopenia (T-score between -1.0 and -2.5) * at least 18 years of age * must be willing to drink tea three times a day for 3 months * must also be willing to come to the study location on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3), * must also be willing to come to the study location to provide urinary, salivary and fecal samples on 2 occasions (baseline and at the end of month 3), * must also be willing to come to the study location to have their blood pressure taken on 4 occasions (baseline, end of month 1, end of month 2, and end of month 3) * must be willing to come to the study location to complete questionnaires on 2 occasions (baseline and at the end of month 3) * must be willing to maintain daily diary for 4 months.

Exclusion criteria

* Women or men with osteoporosis * Women or men with osteopenia due to hyperparathyroidism, multiple myeloma, metastatic bone disease, chronic steroid use * Women or men who are on any bone therapies (i.e. bisphosphonates, selective estrogen receptor modulators, hormone therapy, teriparatide, and denosumab) * Women or men with chronic obstructive pulmonary disease (COPD) * Women or men who smoke

Design outcomes

Primary

MeasureTime frameDescription
The Effect of 3 month Herbal Tea on Changes in Human Type 1 Collagen C-telopeptide (CTx) levels3 monthsUrinary CTx levels will be measured at times month 0 (baseline) and month 3
The Effect of 3 month Herbal Tea on Changes in Human Procollagen Type 1 Intact N-terminal Propeptide (Total P1NP) levels3 monthsUrinary P1NP levels will be measured at times month 0 (baseline) and month 3
The Effect of 3 month Herbal Tea on Changes in the Ratio of CTx:P1NP3 monthsUrinary CTx:P1NP levels will be measured at times month 0 (baseline) and month 3

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026